BTW, DOWNLOAD part of BraindumpsPrep CCDM dumps from Cloud Storage: https://drive.google.com/open?id=1QC68AwqCZT9wdXpqwUXLrMeaguUlgECi
Before you take the exam, you only need to spend 20 to 30 hours to practice, so you can schedule time to balance learning and other things. Of course, you care more about your passing rate. If you choose our CCDM exam guide, under the guidance of our CCDM exam torrent, we have the confidence to guarantee a passing rate of over 99%. Our CCDM quiz prep is compiled by experts based on the latest changes in the teaching syllabus and theories and practices. So our CCDM Quiz prep is quality-assured, focused, and has a high hit rate. The most important information is conveyed with the minimum number of questions, and you will not miss important knowledge. You can make full use of your usual piecemeal time to learn our CCDM exam torrent. You will get the best results in the shortest time. Join our study and you will have the special experience.
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
| Topic 3 |
|
| Topic 4 |
|
| Topic 5 |
|
>> Relevant CCDM Exam Dumps <<
Many candidates find the SCDM CCDM exam preparation difficult. They often buy expensive study courses to start their SCDM CCDM certification exam preparation. However, spending a huge amount on such resources is difficult for many SCDM CCDM Exam applicants.
NEW QUESTION # 71
Based on the project Gantt chart as of 01 Nov 2019, an interim analysis is scheduled to occur early Q2 of 2020. All of the following are valid for initially assessing the status of data cleanliness EXCEPT:
Answer: B
Explanation:
When initially assessing data cleanliness in preparation for an interim analysis, the focus should be on outstanding issues that could affect data completeness and reliability.
According to the GCDMP (Chapter: Data Quality Assurance and Control), key indicators of readiness include:
The CRF data entry status of received pages (option A) to confirm completeness.
Identification of missing pages or visits (option B) to verify subject-level completeness.
A listing of outstanding discrepancies and their aging (option D) to assess unresolved data issues.
Counting the number of discrepancies resolved to date (option C), however, does not reflect data quality or current data readiness-it indicates past actions rather than current unresolved risks. Therefore, it is not a valid measure for assessing interim data cleanliness.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 6.1 - Data Readiness Assessments for Analysis ICH E6 (R2) GCP, Section 5.18.4 - Ongoing Data Quality Review FDA Guidance for Industry: Oversight of Clinical Investigations - Risk-Based Monitoring, Section 7 - Data Quality Indicators
NEW QUESTION # 72
Which document describes what study subjects expect with respect to data disclosure during and after a study?
Answer: C
Explanation:
The Informed Consent Form (ICF) is the document that explicitly describes what study subjects can expect regarding data disclosure, privacy, and confidentiality during and after participation in a clinical trial. According to ICH E6 (R2) Good Clinical Practice and FDA Human Subject Protection Regulations (21 CFR Parts 50 and 56), participants must be fully informed about how their personal and clinical data will be collected, used, stored, and shared - both during the study and in any subsequent data-sharing or publication activities.
The GCDMP reiterates that clinical data managers must ensure that all data handling practices align with the privacy commitments made in the ICF. This includes compliance with data protection regulations such as HIPAA (in the U.S.) and GDPR (in the EU). The ICF defines the permissible scope of data use, ensuring ethical management and subject protection.
Documents like the protocol or data sharing plan may outline procedures and responsibilities but do not directly inform participants of their rights and data use expectations. Only the ICF is designed for that ethical communication purpose.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Ethics, Privacy, and Data Security ICH E6 (R2) Good Clinical Practice, Sections 4.8.10 & 4.8.12 FDA 21 CFR Part 50 - Protection of Human Subjects, Informed Consent Requirements
NEW QUESTION # 73
A sponsor may transfer responsibility for any or all of their obligations to a contract research organization. Which of the following statements is true?
Answer: C
Explanation:
Under ICH E6 (R2) Good Clinical Practice and 21 CFR Part 312.52, when a sponsor delegates or transfers obligations for a clinical trial to a Contract Research Organization (CRO), there must be a written description of each specific obligation being assumed by the CRO.
According to the Good Clinical Data Management Practices (GCDMP), while sponsors may outsource responsibilities such as data management, monitoring, or biostatistics, ultimate accountability remains with the sponsor. The documentation of the transfer of responsibilities ensures regulatory transparency and compliance.
This written agreement, often referred to as a Transfer of Obligations (TOO) document, defines exactly which duties the CRO is responsible for (e.g., CRF design, data cleaning, database lock), as well as any retained sponsor oversight. A general statement that "all obligations are transferred" (option D) is insufficient per regulatory expectations, as sponsors must retain traceability of responsibility.
Therefore, Option B is correct - a detailed written description of transferred obligations is required.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Compliance and Oversight, Section 5.2 - Sponsor and CRO Responsibilities ICH E6 (R2) Good Clinical Practice, Section 5.2.1 - Transfer of Trial-Related Duties and Functions FDA 21 CFR 312.52 - Transfer of Obligations to a Contract Research Organization
NEW QUESTION # 74
Every database lock should follow documented approval of which stakeholders?
Answer: D
Explanation:
According to the Good Clinical Data Management Practices (GCDMP), the database lock (DBL) process signifies the formal closure of the clinical trial database, ensuring that no further changes can be made to the data before statistical analysis. This process must be documented, controlled, and approved by key study stakeholders to ensure data accuracy, completeness, and readiness for analysis.
The GCDMP specifies that database lock should occur only after all data cleaning, discrepancy resolution, and reconciliation activities are complete. The lock authorization typically requires the approval of the Clinical/Scientific Representative (to confirm clinical completeness), the Data Manager (to confirm data integrity and query closure), and the Biostatistician (to confirm readiness for statistical analysis).
This tri-party approval ensures that the database reflects final, verified data consistent with the clinical protocol, and that the statistical analysis dataset derived from the database is accurate and auditable. The approval process is documented via a Database Lock Authorization Form or Sign-off Log, which becomes part of the permanent trial master file (TMF).
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Lock and Archiving, Section 7.1 - Lock Procedures and Approvals ICH E6 (R2) GCP, Section 5.5.3 - Data Handling and Record Keeping FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section on Database Closure
NEW QUESTION # 75
During testing of an ePRO system, a test fails. Which information should be found in the validation documentation?
Answer: D
Explanation:
When a system validation test fails during Electronic Patient-Reported Outcome (ePRO) system testing, the validation documentation must record the expected results (what should have occurred) and the actual results (what occurred).
According to the GCDMP (Chapter: Database Validation and Testing), proper system validation documentation ensures traceability, reproducibility, and compliance with FDA 21 CFR Part 11 and ICH E6 (R2). Each test case must include:
Test objective,
Preconditions,
Test steps,
Expected results,
Actual results, and
Pass/fail status.
If a test fails, this documentation provides the objective evidence necessary for deviation handling, issue resolution, and re-testing. While a separate root cause analysis may be performed later (option D), the validation record itself must focus on verifying outcomes against predefined expectations.
Therefore, the correct answer is B - Expected and actual results.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Validation and Testing, Section 4.4 - Documentation of Test Results FDA 21 CFR Part 11 - Validation Requirements (Section 11.10(a)) ICH E6 (R2) GCP, Section 5.5.3 - Computer System Validation and Documentation
NEW QUESTION # 76
......
After you purchase our CCDM study material, you must really absorb the content in order to pass the exam. Our CCDM guide quiz really wants you to learn something and achieve your goals. And it is easy and convenient for you to make it. For we have three versions of the CCDM Exam Questions for you to choose: the PDF, Software and APP online. So that you can study at any time you like. And the content of the CCDM learning braindumps is also simplified for you to easily understand.
Exam CCDM Learning: https://www.briandumpsprep.com/CCDM-prep-exam-braindumps.html
BTW, DOWNLOAD part of BraindumpsPrep CCDM dumps from Cloud Storage: https://drive.google.com/open?id=1QC68AwqCZT9wdXpqwUXLrMeaguUlgECi